{"altmetric_id":2313914,"citation":{"altmetric_jid":"ecancerorg","first_seen_on":"2014-04-29T23:14:30+00:00","issns":[],"journal":"ecancer","last_mentioned_on":1398424740,"links":["http:\/\/ecancer.org\/video\/2577\/exciting-new-developments-in-the-treatment-of-multicentric-castleman-disease.php"],"title":"Exciting new developments in the treatment of multicentric Castleman disease. Exciting new developments in the treatment of multicentric Castleman disease","type":"article","uri":"http:\/\/ecancer.org\/video\/2577\/exciting-new-developments-in-the-treatment-of-multicentric-castleman-disease.php"},"altmetric_score":{"score":7,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":7},"context_for_score":{"all":{"total_number_of_other_articles":3691748,"mean":4.9608185831835,"rank":448305,"this_scored_higher_than_pct":87,"this_scored_higher_than":3224518,"rank_type":"exact","sample_size":3691748,"percentile":87},"similar_age_3m":{"total_number_of_other_articles":94830,"mean":7.1174167817861,"rank":13685,"this_scored_higher_than_pct":84,"this_scored_higher_than":80451,"rank_type":"exact","sample_size":94830,"percentile":84},"this_journal":{"total_number_of_other_articles":5027,"mean":2.4765893354556,"rank":398,"this_scored_higher_than_pct":89,"this_scored_higher_than":4513,"rank_type":"exact","sample_size":5027,"percentile":89},"similar_age_this_journal_3m":{"total_number_of_other_articles":1,"mean":0,"rank":1,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":1,"percentile":1}}},"demographics":[],"counts":{"news":{"unique_users_count":1,"unique_users":["ecancer"],"posts_count":1},"total":{"posts_count":1}},"posts":{"news":[{"title":"Siltuximab approved for rare Castlemans's disease","url":"http:\/\/ecancer.org\/news\/5597-siltuximab-approved-for-rare-castlemans-s-disease.php","license":"public","citation_ids":[2313914],"posted_on":"2014-04-25T11:19:00+00:00","summary":"The U.S. Food and Drug Administration approved siltuximab (Sylvant) to treat patients with multicentric Castleman\u2019s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes). MCD causes an abnormal overgrowth of immune cells in...","author":{"name":"ecancer","url":"http:\/\/ecancer.org\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/075\/normal\/image.png?1369859451"}}]}}